


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
CATEGORY 1 INNOVATIVE DRUG “ROVADICITINIB (TQ05105)” OBTAINED
POSITIVE RESULTS IN KEY CLINICAL RESEARCH FOR REGISTRATION

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the key clinical research for registration of “Rovadicitinib (TQ05105)”, a Category 1 innovative drug independently researched and developed by the Group for the treatment of moderate and high-risk myelofibrosis (MF), has met the primary endpoint. The Group has communicated with the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the PRC regarding the marketing application of TQ05105 tablets and obtained the CDE’s consent to submit the application for marketing of this product. The Group will recently submit the application for marketing of TQ05105 tablets.

TQ05105 is a JAK/ROCK inhibitor with new chemical structure independently researched and developed by the Group. The results of in vitro test showed that TQ05105 could effectively inhibit the activity of JAK family kinases and ROCK kinase, and significantly inhibit the phosphorylation levels of STAT3 and STAT5 in cells, thereby inhibiting the conduction of JAK/STAT signaling pathway, and in turn exerting anti-tumor activity.

The Group announced the findings of the Phase I clinical research of TQ05105 for the treatment of myeloproliferative neoplasms (MPN) at the Annual Meeting 2023 of American Society of Hematology (ASH). The results showed that TQ05105 had good human pharmacokinetic behavior, good safety and tolerable toxicity, and the efficacy on spleen shrinkage (with the best spleen shrinkage rate of 63.79%) and the improvement of patients’ physical symptoms (with the best improvement rate of 87.50%) was significant, and the duration of effectiveness was long, which could bring more clinical options to MF patients.

In addition, the Group presented the findings from the Phase Ib/II clinical research of TQ05105 in chronic graft-versus-host disease (cGVHD) at the Annual Meeting 2023 of European Hematology Association (EHA). The results showed that TQ05105 had a good safety profile and a high remission rate for each rejection organ site (with the best objective response rate of 86.7%), and significantly improved clinical symptoms (40% of patients improved LSS score by ≥ 7 points), with 73.3% of patients reduced the dose of corticosteroids, which is expected to bring better clinical treatment options for patients with cGVHD.

MF is a diffuse bone marrow fibrous tissue proliferative disorder that belongs to the category of MPN and eventually progresses to the bone marrow failure or transforms into acute leukemia. In September 2023, primary myelofibrosis (PMF) was included in China's Second Batch of Rare Disease List. Only one product has currently been approved for the treatment of MF patients in China, and there is a large unmet clinical demand.

The Group has also deployed a number of joint researches in the field of myelofibrosis, such as clinical research of TQ05105 in combination with BET inhibitors or BCL-2 inhibitors for the treatment of moderate and high-risk myelofibrosis, and the preliminary results are quite positive. TQ05105 is another Category 1 innovative drug that the Group will apply for marketing soon. With continuous investment in the research and development of innovative drugs, the Group's innovative products have made continuous breakthroughs, and the Group's innovation pipeline has entered the harvest period.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 18 April 2024

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.